Literature DB >> 23728943

Identification of driver genes in hepatocellular carcinoma by exome sequencing.

Sean P Cleary1, William R Jeck, Xiaobei Zhao, Kui Chen, Sara R Selitsky, Gleb L Savich, Ting-Xu Tan, Michael C Wu, Gad Getz, Michael S Lawrence, Joel S Parker, Jinyu Li, Scott Powers, Hyeja Kim, Sandra Fischer, Maha Guindi, Anand Ghanekar, Derek Y Chiang.   

Abstract

UNLABELLED: Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma (HCC). As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in HCC. We performed whole-exome sequencing on 87 HCCs and matched normal adjacent tissues to an average coverage of 59×. The overall mutation rate was roughly two mutations per Mb, with a median of 45 nonsynonymous mutations that altered the amino acid sequence (range, 2-381). We found recurrent mutations in several genes with high transcript levels: TP53 (18%); CTNNB1 (10%); KEAP1 (8%); C16orf62 (8%); MLL4 (7%); and RAC2 (5%). Significantly affected gene families include the nucleotide-binding domain and leucine-rich repeat-containing family, calcium channel subunits, and histone methyltransferases. In particular, the MLL family of methyltransferases for histone H3 lysine 4 were mutated in 20% of tumors.
CONCLUSION: The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of HCC.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728943      PMCID: PMC3830584          DOI: 10.1002/hep.26540

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4.

Authors:  Jeongkyung Lee; Dae-Hwan Kim; Seunghee Lee; Qi-Heng Yang; Dong Kee Lee; Soo-Kyung Lee; Robert G Roeder; Jae W Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

3.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Authors:  Derek Y Chiang; Augusto Villanueva; Yujin Hoshida; Judit Peix; Philippa Newell; Beatriz Minguez; Amanda C LeBlanc; Diana J Donovan; Swan N Thung; Manel Solé; Victoria Tovar; Clara Alsinet; Alex H Ramos; Jordi Barretina; Sasan Roayaie; Myron Schwartz; Samuel Waxman; Jordi Bruix; Vincenzo Mazzaferro; Azra H Ligon; Vesna Najfeld; Scott L Friedman; William R Sellers; Matthew Meyerson; Josep M Llovet
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

4.  Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.

Authors:  Mohini A Patil; Ines Gütgemann; Ji Zhang; Coral Ho; Siu-Tim Cheung; David Ginzinger; Rui Li; Karl J Dykema; Samuel So; Sheung-Tat Fan; Sanjay Kakar; Kyle A Furge; Reinhard Büttner; Xin Chen
Journal:  Carcinogenesis       Date:  2005-07-06       Impact factor: 4.944

5.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.

Authors:  Wolfgang Sieghart; Doris Losert; Sabine Strommer; Daniel Cejka; Katharina Schmid; Susanne Rasoul-Rockenschaub; Martin Bodingbauer; Richard Crevenna; Brett P Monia; Markus Peck-Radosavljevic; Volker Wacheck
Journal:  J Hepatol       Date:  2005-10-25       Impact factor: 25.083

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells.

Authors:  Chun-Qi Li; Min Young Kim; Luiz C Godoy; Apinya Thiantanawat; Laura J Trudel; Gerald N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-11       Impact factor: 11.205

8.  Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Jian Huang; Qing Deng; Qun Wang; Kun-Yu Li; Ji-Hong Dai; Niu Li; Zhi-Dong Zhu; Bo Zhou; Xiao-Yan Liu; Rui-Fang Liu; Qian-Lan Fei; Hui Chen; Bing Cai; Boping Zhou; Hua-Sheng Xiao; Lun-Xiu Qin; Ze-Guang Han
Journal:  Nat Genet       Date:  2012-08-26       Impact factor: 38.330

9.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Authors:  Yujin Hoshida; Augusto Villanueva; Masahiro Kobayashi; Judit Peix; Derek Y Chiang; Amy Camargo; Supriya Gupta; Jamie Moore; Matthew J Wrobel; Jim Lerner; Michael Reich; Jennifer A Chan; Jonathan N Glickman; Kenji Ikeda; Masaji Hashimoto; Goro Watanabe; Maria G Daidone; Sasan Roayaie; Myron Schwartz; Swan Thung; Helga B Salvesen; Stacey Gabriel; Vincenzo Mazzaferro; Jordi Bruix; Scott L Friedman; Hiromitsu Kumada; Josep M Llovet; Todd R Golub
Journal:  N Engl J Med       Date:  2008-10-15       Impact factor: 91.245

10.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

View more
  128 in total

Review 1.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

Review 2.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

Review 3.  Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Nat Rev Clin Oncol       Date:  2014-01-07       Impact factor: 66.675

Review 4.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 5.  Examining the impact of gene variants on histone lysine methylation.

Authors:  Capucine Van Rechem; Johnathan R Whetstine
Journal:  Biochim Biophys Acta       Date:  2014-05-23

6.  Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations.

Authors:  Peter Chianchiano; Maryam Kherad Pezhouh; Amy Kim; Claudio Luchini; Andrew Cameron; Matthew J Weiss; Jin He; Lysandra Voltaggio; Kiyoko Oshima; Robert A Anders; Laura D Wood
Journal:  Hum Pathol       Date:  2017-11-24       Impact factor: 3.466

Review 7.  Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Authors:  Kiruthikah Thillai; Paul Ross; Debashis Sarker
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

8.  DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma.

Authors:  Guiji Zhang; Xia Tang; Li Liang; Wanfeng Zhang; Dewei Li; Xiaoyuan Li; Dachun Zhao; Yaqiu Zheng; Yanhong Chen; Bingtao Hao; Kai Wang; Ni Tang; Keyue Ding
Journal:  Oncogene       Date:  2020-02-19       Impact factor: 9.867

Review 9.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

Review 10.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.